Global Gastrointestinal Diseases Market

Gastrointestinal Diseases Market size was valued at US$ 23.28 Bn. in 2022 and the total Gastrointestinal Diseases revenue is expected to grow at 6.8% through 2023 to 2029, reaching nearly US$ 36.90 Bn.

Gastrointestinal Diseases Market Overview:

Diarrhea, stomach discomfort, abdominal discomfort, gastrointestinal hemorrhage, intestinal blockage, malabsorption, or malnourishment are some of the most prevalent symptoms of gastrointestinal illnesses in tropical nations. Adolescent infectious diarrheal illnesses are a leading source of morbidity and death. Acute and chronic diarrheal disorders, as well as a variety of ailments affecting the oral, oesophagus, gastric, biliary, and endocrine systems; small and large intestine; and rectum and anus, are all covered by this field. Improvements in hygiene and socio-economic status have lowered the impact of many serious diseases, but they have also been linked to the appearance of formerly rare diseases in the tropics, e.g. inflammatory bowel disorder and celiac disorder

Symptoms and disorders of the gastrointestinal system are among the most prevalent and (possibly after acute respiratory infections) the most troublesome of clinical conditions in Common variable immunodeficiency. Infectious, inflammatory, immunological, or malignant disorders are the most common causes of these illnesses. A gastrointestinal condition was found in 27 of 50 variable immunodeficiency individuals in one early report, including diarrhea, steatorrhea, giardiasis, achlorhydria, and abnormal small intestine biopsy results.To know about the Research Methodology :- Request Free Sample Report

In this report, the Gastrointestinal Diseases market's growth reasons, as well as the market's many segments (Drug Type, Dosage Form, Application, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Gastrointestinal Diseases market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Gastrointestinal Diseases market situation.

Gastrointestinal Diseases Market Dynamics:

Many governments imposed severe limits on in-person counseling during the COVID-19 crisis. As a result, stenting operations in clinics and private practices have decreased, and evaluations are now conducted via telemedicine visits, with smartphone appointments being the most efficient. In most hospital environments, this has had an impact on the acceptance of gastrointestinal stents.

One of the top causes of mortality globally is gastrointestinal cancer. Chronic illnesses including esophageal cancer, colon cancer, and gastrointestinal-related severe illnesses have seen a sharp increase in morbidities in recent years. In 2021, gastrointestinal malignancies represented 27.5% of worldwide cancer cases and 33.5% of all cancer-related deaths, as per the International Agency for Research on Cancer. According to the World Health Organization, gastrointestinal malignancies such as colon cancer caused nearly a million deaths worldwide in 2021, with stomach cancer accounting for nearly half a million fatalities. With over 2 million new cases identified in 2021, colon cancer was the third most prevalent disease worldwide.

Also, in most Asian nations, government payment for endoscopy stenting treatments is restricted or non-existent, which is one of the key reasons for client and clinician aversion to gastrointestinal stents. The massive price of gastrointestinal stents and the absence of coverage in developing countries like India are predicted to hinder patient uptake of these treatments. Both developed and developing cities are rapidly concentrating their efforts on bolstering and sustaining their indigenous medical device sectors. The continued deployment of rigorous rules for imported medical devices, which boosts the sales and acceptance of regionally created medical equipment, is predicted to diminish global healthcare profit margins.

Gastrointestinal Diseases Market Segment Analysis:

By Drug Type, the antacid segment is expected to witness a CAGR of 4.3% in the previously mentioned forecast period. The expanding older population experiencing Gastroesophageal Reflux Disease, poor physical health leading to greater occurrences of acidity, and adverse effects of medications e.g. non-steroidal anti-inflammatory drugs are all driving the advancement of the antacids segment.

Acidic problems are uncommon in the older population, making it a unique issue for both the primary care doctor and the gastroenterologist. Furthermore, such individuals are more likely to have a number of bothersome illnesses, such as esophagitis, Barrett esophagus, and throat cancer, which require a combination of medications to cure, and the usage of antacids is substantially higher in these situations.

Moreover, e-commerce is on the rise, which is expected to boost antacid consumption through internet retail outlets in the forecast period. As a result, increased e-commerce prominence and growth in the number of online medication suppliers are likely to boost the segment's overall growth. However, the expanding number of antacid substitutes on the market, as well as consumers' ignorance of acidity symptoms, are likely to have a detrimental influence on the segment's growth.

Regional Insights:

In 2022, the North American market held the highest share, and this is projected to continue over the projection period. This significant percentage can be linked to a significant shift in lifestyle, which has resulted in an increase in the prevalence of gastrointestinal disorders. Furthermore, the market is projected to be driven by state programs targeted at preventing and treating gastrointestinal illnesses. For example, UNICEF and World Health Organization's Integrated Global Action Plan for Diarrhoea seek to reduce avoidable pediatric diarrhea fatalities by delivering interventions and solutions to build awareness and allow access to therapy and prevention efforts.

As per the Chinese Society of Digestive Endoscopy, the number of Gastrointestinal endoscopic operations performed in China declined dramatically from 2.9 million in 2021 to 1.3 million in 2021, according to a study. By early 2022, almost all medical equipment markets had completely recovered from the outbreak's severe drop in product sales. The development of the Omicron variety, on the other hand, might jeopardize the demand for endoscopic medical device sales and result in more discretionary treatments being canceled. Markets may, however, rebound in the forecast period as a result of the continuous global vaccination race and the delivery of booster injections.

In recent years, the medical cost has grown drastically throughout the world, as have the costs of medical devices e.g. Gastrointestinal stents. As per research published in May 2021, the estimated price of an endoscopic stenting treatment is US$ 45,000. In developing nations like India and Brazil, medical providers and consumers have limited financial means to spend on such a pricey surgery.

The objective of the report is to present a comprehensive analysis of the Gastrointestinal Diseases market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Gastrointestinal Diseases market dynamics, structure by analyzing the market segments and projecting the Gastrointestinal Diseases market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Gastrointestinal Diseases market make the report investor’s guide.

Gastrointestinal Diseases Market Scope: Inquire before buying

Gastrointestinal Diseases Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Gastrointestinal Diseases Market Key Players

1. Abbott Laboratories
2. Abbvie Inc.
3. AstraZeneca Plc
4. Bayer AG
5. GlaxoSmithKline PLC
6. Janssen Pharmaceuticals Inc.
7. Pfizer Inc.
8. AbbVie Inc.
9. Takeda Pharmaceutical Company Limited
10.Bausch Health Companies Inc.
11.Boehringer Ingelheim GmbH
12.Cipla Inc
13.Merck & Co. Inc.
14.UCB SA
15.Allergan

FAQs:

1. Which is the potential market for Gastrointestinal Diseases in terms of the region?
Ans. In 2022, the North American market held the highest share.

2. What are the restraints for new market entrants?
Ans. Also, in most Asian nations, government payment for endoscopy stenting treatments is restricted or non-existent

3. What is expected to drive the growth of the Gastrointestinal Diseases market in the forecast period?
Ans. One of the top causes of mortality globally is gastrointestinal cancer

4. What is the projected market size & growth rate of the Gastrointestinal Diseases Market?
Ans. Gastrointestinal Diseases Market size was valued at US$ 23.28 Bn. in 2022 and the total Gastrointestinal Diseases revenue is expected to grow at 6.8% through 2023 to 2029, reaching nearly US$ 36.90 Bn.

5. What segments are covered in the Gastrointestinal Diseases Market report?
Ans. The segments covered are Drug Type, Dosage Form, Application, and Region.